ERAS · Erasca Inc
United States · RS rating 37 · As of 2026-10-14
| Price | 14.70 USD |
|---|---|
| 1-day change | -0.5% |
| RS rating (overall / 1M / 3M / 12M) | 37 / 24 / 17 / 99 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 39 / 44 / 34 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +9.1% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +34.6% |
| Market cap (USD) | $7.0B |